HIF1AN Human
Description
HIF1AN Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 349 amino acids (1-349) and having a molecular mass of 40.2kDa.
The HIF1AN is purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Hypoxia-Inducible Factor-1 Alpha (HIF-1α) is a crucial transcription factor that plays a significant role in cellular response to low oxygen levels (hypoxia). It is a subunit of the heterodimeric transcription factor HIF-1, which is composed of HIF-1α and the aryl hydrocarbon receptor nuclear translocator (ARNT or HIF-1β). HIF-1α is encoded by the HIF1A gene and is considered the master regulator of the cellular and developmental response to hypoxia .
HIF-1α contains several important domains, including a basic helix-loop-helix (bHLH) domain, two Per-ARNT-Sim (PAS) domains, and a C-terminal transactivation domain (CTAD). These domains are essential for its stability, dimerization with HIF-1β, and transcriptional activity . Under normoxic conditions, HIF-1α is rapidly degraded via the ubiquitin-proteasome pathway. However, under hypoxic conditions, HIF-1α is stabilized, translocates to the nucleus, dimerizes with HIF-1β, and activates the transcription of various genes involved in angiogenesis, metabolism, and cell survival .
HIF-1α is overexpressed in many human cancers and is heavily implicated in promoting tumor growth and metastasis through its role in initiating angiogenesis and regulating cellular metabolism to overcome hypoxia . Additionally, HIF-1α plays a role in other pathophysiologies, including chronic obstructive pulmonary disease (COPD) and sepsis .
The development of HIF-1α inhibitors, including human recombinant versions, aims to target the dysregulated HIF-1α pathway in various diseases. These inhibitors can potentially suppress tumor growth and metastasis by inhibiting HIF-1α’s ability to activate hypoxia-responsive genes. The therapeutic potential of HIF-1α inhibitors is being explored in preclinical and clinical studies for cancer and other hypoxia-related diseases .
HIF-1α inhibitors work by preventing the stabilization and activity of HIF-1α under hypoxic conditions. This can be achieved through various mechanisms, such as promoting the degradation of HIF-1α, inhibiting its dimerization with HIF-1β, or blocking its transcriptional activity. By targeting HIF-1α, these inhibitors aim to disrupt the hypoxia-induced signaling pathways that contribute to disease progression .
